The Technical Analyst
Sera Prognostics, Inc. [SERA]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Sera Prognostics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-1.53% $9.64
America/New_York / 19 apr 2024 @ 11:23
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 303.25 mill |
| EPS: | -1.160 |
| P/E: | -8.31 |
| Earnings Date: | N/A |
| SharesOutstanding: | 31.46 mill |
| Avg Daily Volume: | 0.234 mill |
| RATING 2024-04-18 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -8.31 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.44x |
| Company: PE -8.31 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.896 (-109.30%) $-10.54 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 8.91 - 10.37 ( +/- 7.60%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-27 | Boniface John J. | Buy | 48 909 | Class A Common Stock |
| 2024-03-28 | Boniface John J. | Buy | 24 474 | Class A Common Stock |
| 2024-03-27 | Boniface John J. | Sell | 48 909 | Class A Common Stock |
| 2024-03-28 | Boniface John J. | Sell | 24 474 | Class A Common Stock |
| 2024-03-27 | Boniface John J. | Sell | 48 909 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 56.52 |
| Last 97 transactions |
| Buy: 4 223 994 | Sell: 1 702 853 |
Forecast:
13:04 - $9.73
Live Trading Signals (every 1 min)
Forecast
1: 11:34 - $9.67
Forecast 2: 12:24 - $9.72
Forecast 3: 13:04 - $9.73
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $9.64 (-1.53% ) |
| Volume | 0.0164 mill |
| Avg. Vol. | 0.234 mill |
| % of Avg. Vol | 7.01 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SERA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:31 | sell | $8.18 | N/A | Active |
|---|
SERA
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Latest Press Releases
2024-03-20 16:05:00 - Press Release
Sera Prognostics Reports Fourth Quarter 2023 Financial Results
Salt lake city , march 20, 2024 /prnewswire/ -- sera prognostics inc., the pregnancy company® (nasdaq: sera), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended december 31, 2023. recent highlights: announced that the data safety monitoring board (dsmb) overseeing sera's pivotal prematurity risk assessment combined with clinical interventions for improved neonatal outcomes (prime) study recommended stopping enrollment due to efficacy, reporting that either of the co-primary endpoints met the stopping criteria for statistical significance at the pre-planned interim analysis.
2024-03-04 08:30:00 - Press Release
Sera Prognostics Announces Conference Call And Webcast Of Fourth Quarter And Fiscal Year 2023 Financial Results On March 20, 2024
Salt lake city , march 4, 2024 /prnewswire/ -- sera prognostics inc., the pregnancy company® (nasdaq: sera), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2023 financial results on wednesday, march 20, after the close of the market. the company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.
2024-02-29 11:14:00 - Press Release
Sera Prognostics To Present At Td Cowen 44th Annual Healthcare Conference
Salt lake city , feb. 29, 2024 /prnewswire/ -- sera prognostics inc., the pregnancy company® (nasdaq: sera), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the td cowen 44th annual healthcare conference on monday, march 4, 2024 at 2:50 p.m. et. zhenya lindgardt, president and ceo, will participate in a fireside chat and provide a company update and discuss sera's latest achievements.
2023-12-06 08:30:00 - Press Release
Sera Prognostics Announces Primary Endpoint Criteria Met In Pivotal Prime Study Interim Look - Enrollment To Stop Due To Success
Salt lake city , dec. 6, 2023 /prnewswire/ -- sera prognostics inc., the pregnancy company® (nasdaq: sera), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the data safety monitoring board (dsmb) overseeing its pivotal prematurity risk assessment combined with clinical interventions for improved neonatal outcomes (prime) study recommended stopping enrollment due to efficacy, reporting that either of the co-primary endpoints met the stopping criteria for statistical significance at the pre-planned interim analysis. the company has adopted the dsmb's recommendation and will stop prime study enrollment to focus on analyzing and reporting the available data.
2023-11-22 13:00:00 - Press Release
Sera Prognostics To Present At 35th Annual Piper Sandler Healthcare Conference
Salt lake city , nov. 22, 2023 /prnewswire/ -- sera prognostics inc., the pregnancy company® (nasdaq: sera), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the upcoming 35th annual piper sandler healthcare conference to be held november 28-30, 2023 in new york city. doug fisher, sera's chief business officer, is scheduled to participate in a presentation on november 28, 2023, at 10:50 a.m.
Latest News
2024-03-25 13:01:05 - Zacks Investment Research
Sera Prognostics (SERA) Upgraded to Buy: Here's What You Should Know
Sera Prognostics (SERA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-03-24 02:15:22 - Seeking Alpha
Sera Prognostics' PreTRM: A Speculative Buy In Women's Health
Sera Prognostics specializes in women's health diagnostics with its PreTRM test, offering personalized risk assessment for preterm birth. The PreTRM test analyzes specific proteins and gestational age to provide accurate risk assessment for preterm birth. Sera Prognostics specializes in women's health through its flagship product, PreTRM, with an 88% sensitivity for predicting preterm births.
2024-03-20 21:53:06 - Seeking Alpha
Sera Prognostics, Inc (SERA) Q4 2023 Earnings Call Transcript
2024-03-20 18:20:16 - Zacks Investment Research
Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.25 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.31 per share a year ago.
2024-02-29 11:14:00 - PRNewsWire
Sera Prognostics To Present at TD Cowen 44th Annual Healthcare Conference
SALT LAKE CITY , Feb. 29, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 44th Annual Healthcare Conference on Monday, March 4, 2024 at 2:50 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements.
2023-12-11 13:32:39 - Zacks Investment Research
Here's Why Sera Prognostics, Inc. (SERA) is a Great Momentum Stock to Buy
Does Sera Prognostics, Inc. (SERA) have what it takes to be a top stock pick for momentum investors? Let's find out.
2023-12-06 13:19:00 - InvestorPlace
Why Is Sera Prognostics (SERA) Stock Up 260% Today?
Amid another soft session on Wall Street, Sera Prognostics (NASDAQ: SERA ) — a specialist in the field of maternal and neonatal health — shook up the market with a dramatic increase in value. Fueling the blistering ride was encouraging data for its clinical study regarding risk assessment of premature delivery.
2023-11-22 13:00:00 - PRNewsWire
SERA PROGNOSTICS TO PRESENT AT 35TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE
SALT LAKE CITY , Nov. 22, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the upcoming 35th Annual Piper Sandler Healthcare Conference to be held November 28-30, 2023 in New York City. Doug Fisher, Sera's Chief Business Officer, is scheduled to participate in a presentation on November 28, 2023, at 10:50 a.m.
2023-11-12 00:35:08 - Seeking Alpha
Sera Prognostics, Inc (SERA) Q3 2023 Earnings Call Transcript
Sera Prognostics, Inc (NASDAQ:SERA ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Peter DeNardo - Investor Relations Zhenya Lindgardt - President and Chief Executive Officer Austin Aerts - Chief Financial Officer Conference Call Participants Maggie Boeye - William Blair Tom Stevens - TD Cowen Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review Third Quarter Fiscal Year 2023 results. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.
2023-10-10 09:01:18 - Zacks Investment Research
Why You Should Bet on These 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Yum Brands (YUM), Inter Parfums (IPAR), TripAdvisor (TRIP) and Sera Prognostics (SERA).